Scott Hecker has over 35 years of industry experience in leading medicinal chemistry and manufacturing in antibacterial drug discovery and development.

He began his industrial career at Pfizer as a medicinal chemist in antibacterial drug discovery and then joined Microcide/Essential Therapeutics, where he led teams in the discovery of novel anti-infective drug candidates. He then moved to Metabasis Therapeutics where he oversaw the discovery and early development of drug candidates for diabetes, hyperlipidemia and hepatitis C in programmes that advanced in development under partnerships with Merck and Roche. He later joined Mpex/Rempex Pharmaceuticals, where he was a founding member of the beta-lactamase inhibitor programme that discovered the now FDA-approved agent vaborbactam. Upon acquisition of Rempex by The Medicines Company, he oversaw the Active Pharmaceutical Ingredient (API) manufacturing of vaborbactam as well as leading medicinal chemistry efforts to identify next-generation agents that are now being developed by Qpex Biopharma.

Scott has authored over 50 publications and is an inventor on over 65 patents. He holds a B.A. in Chemistry from Wesleyan University and a PhD in Chemistry from the University of California, Berkeley.